Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 89

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2018

Summary

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene.

It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response.

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) pipeline Target constitutes close to 23 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 2, 1, 8 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Non Malignant Disorders which include indications Breast Cancer, Prostate Cancer, Colon Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Breast Cancer, Ovarian Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenomas, Colorectal Cancer, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pancreatic Cancer, Refractory Acute Myeloid Leukemia and Relapsed Acute Myeloid Leukemia.

The latest report Mucin 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)

- The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Overview
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
Bavarian Nordic A/S
Bioleaders Corp
Boehringer Ingelheim GmbH
Etubics Corp
GeoVax Labs Inc
Merck KGaA
Minerva Biotechnologies Corp
NantKwest Inc
Peptron Inc
Transgene SA
Vaxil Bio Therapeutics Ltd
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Drug Profiles
BI-1361849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLSM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target MUC1 for Gastric Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-051 + ETBX-061 + ETBX-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEOCM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GI-6108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GO-203/NPs - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GO-2032c - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ImMucin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit MUC1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit MUC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit MUC1 for Metastatic Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tecemotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Castration Resistant Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MUC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MUC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MUC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MUC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MUC1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Mucin 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Dormant Products
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Discontinued Products
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer
May 03, 2018: Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy Treatment
Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
Jan 16, 2018: First Patient Dosed in a Phase 2 Trial with Transgene TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
Oct 30, 2017: Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
Oct 12, 2017: Peer Reviewed Scientific Publications Highlight TG4010's Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
Oct 09, 2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress
Sep 11, 2017: Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer
Aug 30, 2017: GeoVax Presents Preliminary Data for Cancer Vaccine
Jul 24, 2017: Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer
May 23, 2017: Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials
Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer
Mar 13, 2017: First Patient Dosed in Phase 2 Trial Evaluating Transgenes TG4010 in Combination With Opdivo (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer
Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer
Mar 03, 2017: Vaxil Announces Novel Immunotherapy Poster Presentation at 2017 American Association for Cancer Research Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Akshaya Bio Inc, H2 2018
Pipeline by Bavarian Nordic A/S, H2 2018
Pipeline by Bioleaders Corp, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Etubics Corp, H2 2018
Pipeline by GeoVax Labs Inc, H2 2018
Pipeline by Merck KGaA, H2 2018
Pipeline by Minerva Biotechnologies Corp, H2 2018
Pipeline by NantKwest Inc, H2 2018
Pipeline by Peptron Inc, H2 2018
Pipeline by Transgene SA, H2 2018
Pipeline by Vaxil Bio Therapeutics Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Immunofluorescence Assays Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 115
    Immunofluorescence is the specific antigen and antibody reaction where the antibodies are labeled with a fluorescent dye and the antigen-antibody complex is visualized using fluorescent (UV) microscope. Some of the commonly used fluorochromes include Acridine Orange, Lissamine, Rhodamine, and Calcofluor white. Various factors determine the type of immunofluorescence assay used such as time consumed, cost, complexity, flexibility, sensitivity, cross reactivity and many others. It is used in all d......
  • Global Hospital Injectable Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 115
    Drug injection is a method of introducing a drug into the bloodstream via a hollow hypodermic needle and a syringe, which is pierced through the skin into the body. Injectable drugs bypasses first-pass metabolism in the liver, resulting in higher bioavailability and efficiency for many drugs (such as morphine or diacetylmorphine/heroin; roughly two-thirds of which is destroyed in the liver when consumed orally) than oral ingestion would, meaning users get a stronger (yet shorter-a......
  • Global HPMC Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Hydroxypropyl methylcellulose (HPMC), also known as hypromellose, is produced through the synthetic alteration of the natural polymer cellulose and is considered safe for human consumption. Read more: http://www.digitaljournal.com/pr/3726329#ixzz5RQbXrzzQ Scope of the Report: The worldwide market for HPMC Capsules is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to......
  • Global Humin Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 118
    Humic substances like humus, humate, fulvic acid, organic matter, and humin play a key role in soil fertility. Plants grown in soil having an adequate amount of humic substances are healthier, produce higher yields; and have superior nutritional quality. Humins are that part of humic substances that not soluble in acids (low pH) or alkalis (high pH). These are not soluble in water at any pH. Humins are macro organic substances as their molecular weights range from approximately 100,000 to 10,000......
  • Global Immune Health Supplements Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 137
    Immune Health Supplements refer to the product which could improve human immune health. Scope of the Report: The worldwide market for Immune Health Supplements is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. This report focuses on the Immune Health Supplements in global market, especially in North America, Europe and Asia-Pacific......
  • Global Immunoglobulins Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 122
    Immunoglobulin's also called as antibodies are large Y-shaped protein produced by B-cell. These are the glycoprotein molecule produced by plasma cells in response to entry of foreign entity such as bacteria and viruses in the body. Production of antibodies is an important function of immune system. Antibodies use binding mechanism for neutralizing the activity of a foreign particle called as an antigen. Scope of the Report: The worldwide market for Immunoglobulins is expec......
  • Global Immunology Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 15-Nov-2018        Price: US 3480 Onwards        Pages: 118
    The immune system is an assembly of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies various threats like bacteria, viruses, and parasites and distinguishes them from body's healthy tissues. When the immune system weakness and lose the capability to detect and destroy the abnormal cells or body attacks and damages its tissues lead to diseases like cancer and autoimmune diseases. Immunotherapy is a process which includes the ......
  • 2018-2023 United States Medicinal Mushroom Extracts Market Report (Status and Outlook)
    Published: 15-Nov-2018        Price: US 3360 Onwards        Pages: 86
    In 2017, the Medicinal Mushroom Extracts market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In United States market, the top players include - Verygrass - Amino Up Chemical - Nammex - Baikal Herbs Ltd. - Johncan international - Aloha Medicinals - Limonnik - Fungi Perfecti - Kangxin - Shaanxi Undersun Biomedtech - GanoHerb......
  • 2018-2023 United States Sexual Enhancement Supplements Market Report (Status and Outlook)
    Published: 15-Nov-2018        Price: US 3360 Onwards        Pages: 89
    In 2017, the Sexual Enhancement Supplements market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In United States market, the top players include - Leading Edge Health - Innovus Pharmaceuticals - Direct Digital - SizeGenix - Vimax - Xanogen - Vydox - TEK Naturals Split by product types/category, covering - Male Sexual Enhancemen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs